ResearcherMayo ClinicActive in the last 2 years
Christopher Hartley
Matched on ORCID iD 0000-0002-2237-3102; OpenAlex author ID A5060543045. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection. Co-author DOI 10.1158/1078-0432.ccr-25-4968↗
- Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.anndiagpath.2020.151485↗
- Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.plabm.2020.e00171↗
- Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000001144↗
- FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplific… Co-author DOI 10.1002/cncy.21935↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daniel J. Rowan · 2 shared papers, 2020 · strength 0.25
- Paper Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant t… DOI 10.1016/j.anndiagpath.2020.151485↗
- Paper Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma. DOI 10.1016/j.plabm.2020.e00171↗
- Khalid Jazieh · 1 shared paper, 2026 · strength 0.23
- Luis Humberto Cisneros · 1 shared paper, 2026 · strength 0.23
- Ben George · 1 shared paper, 2026 · strength 0.23
- Cornelius A. Thiels · 1 shared paper, 2026 · strength 0.23
- Mark Joseph Truty · 1 shared paper, 2026 · strength 0.23
- Ryan Michael Carr · 1 shared paper, 2026 · strength 0.23
- Robert R. McWilliams · 1 shared paper, 2026 · strength 0.23
- Martín E. Fernández-Zapico · 1 shared paper, 2026 · strength 0.23
- Catherine E. Hagen · 1 shared paper, 2020 · strength 0.13
- Alexander Craig Mackinnon · 1 shared paper, 2020 · strength 0.13
- Mohammed Aldakkak · 1 shared paper, 2020 · strength 0.13
- Douglas B. Evans · 1 shared paper, 2020 · strength 0.13
- Susan Tsai · 1 shared paper, 2020 · strength 0.13
- Kathleen K. Christians · 1 shared paper, 2020 · strength 0.13
- William M. Rehrauer · 1 shared paper, 2017 · strength 0.10
- William G. Hawkins · 1 shared paper, 2018 · strength 0.09
- Deyali Chatterjee · 1 shared paper, 2018 · strength 0.09
- Iván González · 1 shared paper, 2018 · strength 0.09
- Roheena Z. Panni · 1 shared paper, 2018 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.